Last reviewed · How we verify
NCT04334356
Testing of a Mobile Web App to Decrease Posttraumatic Stress Symptoms in Women After Sexual Assault
NA trial testing Mobile Web App in Posttraumatic Stress Disorder in 25 participants. Completed in 18 November 2022.
18 November 2022
Quick facts
| Lead sponsor | University of North Carolina, Chapel Hill |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | prevention |
| Enrollment | 25 |
| Start date | 30 May 2020 |
| Primary completion | 18 November 2022 |
| Estimated completion | 18 November 2022 |
| Sites | 2 locations across United States |
Drugs / interventions tested
- Mobile Web App
Conditions studied
- Posttraumatic Stress Disorder — all drugs for Posttraumatic Stress Disorder →
Sponsor
University of North Carolina, Chapel Hill
Who can join
Adults 18 to 99, female only, with Posttraumatic Stress Disorder. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Interventions are available to all adult women sexual assault survivors to reduce the risk of pregnancy and sexually transmitted infection, yet no interventions are provided to reduce posttraumatic stress. This pilot study tests the ability of a smartphone-based web app to prevent and reduce posttraumatic stress in women sexual assault survivors.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04334356
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Mobile Web App
Trials testing the same drug.
- NCT06232356 — Screening for Lung Health by a Mobile Device · unknown
Other recruiting trials for Posttraumatic Stress Disorder
Currently open trials in the same condition.
- NCT04529031 — Biomolecular Characteristics of Reminder-Focused Positive-Psychiatry · NA · recruiting
- NCT06219408 — CIH Stepped Care for Co-occurring Chronic Pain and PTSD · NA · recruiting
- NCT07176273 — Adaptive Decision-making And Personalized Treatment for PTSD (ADAPT-PTSD) · NA · recruiting
- NCT07105345 — Exploring Efficacy of Multi-Mode Cognitive Processing Therapy (CPT) for PTSD · NA · recruiting
- NCT06608277 — Ketamine, SGB and Combination Treatment for TBI · Phase 2 · recruiting
Other University of North Carolina, Chapel Hill trials
Trials by the same sponsor.
- NCT06841913 — Woodsmoke Exposure, Influenza Infection, and Nasal Immunity · Phase 4 · suspended
- NCT07383428 — The INICIO-Guatemala Study · NA · not yet recruiting
- NCT07528443 — Ultraprocessed Foods in Colombia · NA · not yet recruiting
- NCT07507370 — CARED : A Novel Rapid Treatment Paradigm for Depression · NA · not yet recruiting
- NCT07534254 — Piloting a Generative Artificial Intelligence Chatbot in a Mobile Weight Loss Program · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04334356 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of North Carolina, Chapel Hill
- Last refreshed: 21 February 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04334356.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing